Gurgaon Samachar

Chronic Inducible Urticaria Pipeline Analysis

Chronic Inducible Urticaria Pipeline constitutes 4+ key companies continuously working towards developing 4+ Chronic Inducible Urticaria treatment therapies, analyzes DelveInsight.

Chronic Inducible Urticaria Overview:

Chronic Inducible Urticaria (CIndU) is a form of chronic hives where symptoms such as welts and itching are brought on by specific physical or environmental triggers—like pressure, temperature changes, sunlight, or physical activity. In contrast to chronic spontaneous urticaria, which has no identifiable cause, CIndU is directly linked to known stimuli and can significantly impact a person’s quality of life, requiring a tailored and comprehensive treatment strategy.

The condition stems from an exaggerated response of mast cells, which release histamine and other inflammatory substances when exposed to triggers, leading to redness, swelling, and itching. Standard treatment includes antihistamines and leukotriene receptor antagonists, with immunomodulators considered in more severe or resistant cases.

Effective management involves both trigger avoidance and symptom control, with patient education being a key component. Continued research is enhancing understanding of CIndU and driving the development of more effective treatment options.

Request for a detailed insights report on Chronic Inducible Urticaria pipeline insights

“Chronic Inducible Urticaria Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Chronic Inducible Urticaria Therapeutics Market.

Key Takeaways from the Chronic Inducible Urticaria Pipeline Report

• DelveInsight’s Chronic Inducible Urticaria pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Chronic Inducible Urticaria treatment.

• In October 2025, Jasper Therapeutics reported preliminary results from its ongoing SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adults with cold urticaria (ColdU) or symptomatic dermographism (SD), two common subtypes of CIndU. Of the 15 participants enrolled, 14 (93%) showed a clinical response within 6 weeks. In the 120mg dose group, 10 out of 12 participants (83%) achieved a complete response, and 1 participant had a partial response. Briquilimab was well tolerated, with no serious adverse events or grade 3 or higher adverse events reported. Jasper has received regulatory approval to enroll a 180mg dose cohort in the study and plans to present full data in the first half of 2025.

• In September 2025, Evommune announced the enrollment of the first patient in a Phase II trial of EVO756 for adults with CIndU.

• In June 2025, Celldex Therapeutics revealed data showing that barzolvolimab significantly improves angioedema at 12 weeks in its Phase II clinical trial for chronic spontaneous urticaria (CSU).

• In May 2025, Novartis shared new data confirming the long-term efficacy and safety of remibrutinib, a selective Bruton’s tyrosine kinase (BTK) inhibitor, in chronic spontaneous urticaria (CSU).

• In March 2025, Jasper Therapeutics announced that the first patient had been dosed in its Phase Ib/IIa (SPOTLIGHT) clinical study of subcutaneous briquilimab for treating CIndU.

• In February 2025, ARS Pharmaceuticals reported positive efficacy results from its Phase II inpatient chronic spontaneous urticaria study using neffy (epinephrine nasal spray), an investigational new drug.

• Key Chronic Inducible Urticaria companies such as Celldex Therapeutics, Jasper Therapeutics, and others are evaluating new drugs for Chronic Inducible Urticaria to improve the treatment landscape.

• Promising Chronic Inducible Urticaria pipeline therapies in various stages of development include Barzolvolimab, and others.

Chronic Inducible Urticaria Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Chronic Inducible Urticaria Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Inducible Urticaria treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Chronic Inducible Urticaria market.

Download our free sample page report on Chronic Inducible Urticaria pipeline insights

Chronic Inducible Urticaria Emerging Drugs

• Barzolvolimab: Celldex Therapeutics

Chronic Inducible Urticaria Companies

Approximately four major companies are involved in developing treatments for Chronic Inducible Urticaria. Of these, Celldex Therapeutics has the most advanced drug candidates, currently in Phase II of clinical development.

DelveInsight’s report covers around 22+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Chronic Inducible Urticaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Chronic Inducible Urticaria Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Chronic Inducible Urticaria Therapies and Key Companies: Chronic Inducible Urticaria Clinical Trials and advancements

Chronic Inducible Urticaria Pipeline Therapeutic Assessment

• Chronic Inducible Urticaria Assessment by Product Type

• Chronic Inducible Urticaria By Stage

• Chronic Inducible Urticaria Assessment by Route of Administration

• Chronic Inducible Urticaria Assessment by Molecule Type

Download Chronic Inducible Urticaria Sample report to know in detail about the Chronic Inducible Urticaria treatment market @ Chronic Inducible Urticaria Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Chronic Inducible Urticaria Current Treatment Patterns

4. Chronic Inducible Urticaria – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Chronic Inducible Urticaria Late-Stage Products (Phase-III)

7. Chronic Inducible Urticaria Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Chronic Inducible Urticaria Discontinued Products

13. Chronic Inducible Urticaria Product Profiles

14. Chronic Inducible Urticaria Key Companies

15. Chronic Inducible Urticaria Key Products

16. Dormant and Discontinued Products

17. Chronic Inducible Urticaria Unmet Needs

18. Chronic Inducible Urticaria Future Perspectives

19. Chronic Inducible Urticaria Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Chronic Inducible Urticaria Pipeline Reports Offerings

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/